Story
GSK Shares Decline After Halting Development of Key Cough Drug
Summary
GSK's stock fell after the pharmaceutical giant discontinued its late-stage cough drug, camlipixant, following inconsistent trial results. The decision marks a significant setback for a pipeline asset acquired in a $2 billion deal.
Shares in GSK plc fell on Wednesday after the company announced it would discontinue the development of camlipixant, a promising treatment for refractory chronic cough. The decision follows inconsistent outcomes in two pivotal late-stage clinical trials, creating a significant setback for the company's respiratory drug pipeline.
Conflicting Trial Results
GSK's decision was prompted by conflicting results from its two Phase 3 trials, CALM-1 and CALM-2. While the CALM-1 study successfully met its primary endpoint by showing a statistically significant reduction in cough frequency, the CALM-2 trial failed to replicate this result.
The company stated that this split outcome left the program without a credible regulatory pathway for approval in the United States, European Union, or Japan. The drug was intended to treat adults with refractory chronic cough.
Financial Implications for GSK
The discontinuation represents a notable pipeline write-down for GSK. The company acquired camlipixant through its $2 billion purchase of Bellus Health in 2023, a deal positioned as a key component of its respiratory franchise.
Ad- The drug was projected to be accretive to GSK's adjusted earnings per share starting in 2027.
- This development setback comes as GSK is also absorbing the financial impact of its recent $10.6 billion all-cash acquisition of Nuvalent, which analysts expect to modestly reduce core earnings per share through 2028.
Market Reaction
GSK stock was trading down approximately 2.6% at 1,906p following the news, after hitting a session low of 1,869p. The decline was exacerbated by a broader risk-off sentiment in global markets, with major indices like the S&P 500 and NASDAQ also trading lower.
While the negative market backdrop contributed to selling pressure, the company-specific news regarding the camlipixant program was the primary driver behind the stock's underperformance.
Read next
More on Stocks
Microsoft Stock Climbs on Analyst Optimism Over Azure Pricing Power
Microsoft shares gained in pre-market trading after a BNP Paribas analyst highlighted upcoming price increases for the Azure cloud platform as a key future growth driver not yet reflected in revenue.
China's Seaborne Oil Imports Remain Subdued, Nearing 1 Billion Barrel Annual Deficit
China's crude oil imports by sea remain significantly below historical levels in September, with the cumulative deficit for the year on track to reach 1 billion barrels, according to data from Vortexa.
Warpaint London Shares Drop 11% on Lowered Full-Year Revenue Outlook
The cosmetics group's stock fell sharply after it signaled full-year 2026 revenue would likely hit the lower end of analyst forecasts, citing a challenging first half.
Micron Stock Edges Lower on Profit-Taking and Competitive Pressures
Shares of Micron Technology slipped in pre-market trading as investors secured profits from a recent rally, while a notable short position and increased competition in the memory market weighed on sentiment.